8-K: STAAR Surgical Navigates China Headwinds with Strategic Turnaround and Strong Global Growth Ex-China

STAAR Surgical Company reports a significant decline in Q1 2025 China sales due to distributor inventory consumption, while other key markets show positive growth, as the company implements a strategic turnaround plan.

Summary

• STAAR Surgical Company (NASDAQ: STAA) will give investor presentations commencing June 4, 2025, sharing a slide presentation detailing its operations and outlook.
• The company is positioned as a global leader in phakic IOLs (Implantable Collamer Lenses) for vision correction, aiming to address the growing myopia epidemic.
• For fiscal year 2024, global sales were $313.9 million, with cash, cash equivalents, and investments totaling $222.8 million as of March 28, 2025.
• Q1 2025 net sales were $42.589 million, representing a 45% year-over-year decline, primarily driven by a 99% drop in China sales (from $38.5 million in Q1 2024 to $389,000 in Q1 2025).
• Excluding China, global sales demonstrated positive growth of 8% year-over-year in Q1 2025, with Americas up 9%, EMEA up 9%, and APAC ex-China up 10%.
• Gross margin in Q1 2025 was temporarily depressed due to the ramp-up of Switzerland manufacturing and increased reserves for excess and obsolete inventory.
• Adjusted EBITDA for Q1 2025 was negative $26.385 million, a significant decrease compared to positive $5.295 million in Q1 2024.
• The company incurred $22.664 million in restructuring, impairment, and related charges in Q1 2025, covering severance, operating lease, machinery and equipment, leasehold improvements, and internally developed software impairments.
• STAAR Surgical's EVO ICL technology is highlighted for its unique benefits, including preserving the tear film and cornea, providing UV protection, being reversible, enabling rapid recovery, and offering improved contrast sensitivity and night vision compared to traditional laser vision correction.
• The company holds over 90% global dollar share of phakic IOLs and approximately 12%+ of the global refractive market share, with a dominant 70%+ share in Japan.
• The total addressable market for myopia correction is estimated at 2.7 billion people (5.4 billion eyes), with only 1 in 400 currently electing a surgical vision correction option.
• Myopia prevalence is projected to increase to nearly 50% of the global population by 2050, indicating a substantial and growing market opportunity.

Sentiment

Score: 6

Explanation: The document presents a mixed picture: significant short-term financial headwinds due to China sales decline and restructuring charges, but also outlines clear strategic actions to address these issues, strong performance in other markets, and a very positive long-term market outlook for its core technology. The tone is confident about a rebound, justifying a slightly positive score despite the negative Q1 financials.

Positives

• STAAR Surgical is the global leader in phakic IOLs for vision correction, holding over 90% global dollar share of phakic IOLs.
• The company maintains a strong market share in Japan (70%+) and is expanding its global refractive market share (12%+).
• EVO ICL technology offers significant competitive advantages over traditional laser vision correction, including corneal and tear film preservation, UV protection, reversibility, rapid recovery, and superior vision quality.
• Despite challenges in China, global sales excluding China showed robust year-over-year growth in Q1 2025 across all key markets: Americas (+9%), EMEA (+9%), and APAC ex-China (+10%).
• The long-term market opportunity is substantial, with 2.7 billion people (5.4 billion eyes) affected by myopia globally and a low current surgical correction rate, indicating significant untapped potential.
• Myopia prevalence is projected to increase to nearly 50% of the global population by 2050, ensuring a growing demand for vision correction solutions.
• Recent regulatory wins include EVO+ (V5) approval in China for toric and sphere, Taiwan EVO ICL approval, and an expanded label in Brazil down to -0.5D.
• Validation of the Swiss manufacturing facility is expected by Summer 2025, which will enable the production of Swiss-made ICLs, anticipated to be free from China tariffs.
• The company has mitigated the potential impact of China tariffs through at least early 2026 via a consignment inventory strategy.
• Management has identified and is implementing actions to significantly reduce costs, targeting a $225 million SG&A run rate by the end of FY25.

Negatives

• Overall net sales in Q1 2025 declined significantly by 45% year-over-year to $42.589 million.
• China sales experienced a drastic 99% year-over-year drop in Q1 2025, falling to $389,000 from $38.5 million in Q1 2024, as distributors consumed existing inventory.
• Gross margin was temporarily depressed in Q1 2025 due to the Switzerland manufacturing ramp-up and increased reserves for excess and obsolete inventory.
• Adjusted EBITDA for Q1 2025 was negative $26.385 million, a substantial decline from positive $5.295 million in Q1 2024.
• The company incurred significant restructuring, impairment, and related charges totaling $22.664 million in Q1 2025.
• Global ICL unit growth was down 48% in Q1 2025, reflecting the impact of the China market slowdown.

Risks

• Ability to continue growth and profitability trajectory.
• Reliance on independent distributors in international markets.
• Slowdown or disruption to the Chinese economy.
• Global economic conditions.
• Fluctuations in foreign currency exchange rates.
• International trade disputes (including involving tariffs) and substantial dependence on demand from Asia.
• Changes in effective tax rate or tax laws.
• Any loss of use of the principal manufacturing facility.
• Competition from other vision correction methods and companies.
• Potential losses due to product liability claims.
• Exposure to environmental liability.
• Data corruption, cyber-based attacks or network security breaches and/or noncompliance with data protection and privacy regulations.
• Acquisitions of new technologies.
• Climate changes impacting operations or supply chain.
• Willingness of surgeons and patients to adopt new or improved products and procedures.
• Extensive clinical trials and resources devoted to research and development.
• Compliance with government regulations.
• Discretion of regulatory agencies to approve or reject existing, new or improved products, or to require additional actions before or after approval, or to take enforcement action.
• Laws pertaining to healthcare fraud and abuse.
• Changes in FDA or international regulations related to product approval.
• Product recalls or failures.

Future Outlook

STAAR Surgical anticipates a rebound in the second half of 2025, with expectations for positive global sales growth in all key markets excluding China. The company projects a meaningful sales lift with the planned resumption of purchases by China distributors commencing Q3 2025. The validation of the Swiss manufacturing facility by Summer 2025 is expected to enable the production of Swiss-made ICLs, which are anticipated to be free from China tariffs. Furthermore, the company is implementing cost reduction actions to achieve a $225 million SG&A run rate by the end of FY25, with an overall expectation to return to historical earnings and cash flow generation.

Management Comments

• "Transition & Turnaround in Progress."
• "China Minimal purchases by China distributors as they continue to work through existing in-country inventory, as expected."
• "Rebound expected: Global Positive global sales growth in all key markets excluding China ~70% 2H25 After Switzerland manufacturing ramp."
• "Short Term Tactical Challenges Have Been Addressed."
• "STAAR is ushering in the next generation of vision correction. Join us on the Journey."
• "Expect Return to Historical Earnings and Cash Flow Generation."
• "Dedicated to Shareholder Transparency and Maximizing Returns."

Industry Context

STAAR Surgical operates within the dynamic global vision correction market, which is significantly influenced by the increasing prevalence of myopia, projected to affect nearly 50% of the global population by 2050. The company strategically positions its EVO ICL as a superior, non-cornea-altering alternative to traditional laser vision correction procedures like LASIK, PRK, and SMILE. This differentiation allows STAAR to address a large and growing unmet need, particularly for patients who are hesitant about surgical solutions or have specific corneal conditions. The current underpenetration of the surgical vision correction market, with only a small fraction of eligible individuals opting for procedures, presents a substantial long-term growth opportunity for STAAR Surgical.

Comparison to Industry Standards

• STAAR Surgical holds a dominant position in its niche, with over 90% global dollar share of phakic IOLs and the #1 refractive market share in Japan (70%+).
• Globally, STAAR commands 12%+ of the refractive market share, competing directly with established laser vision correction procedures such as LASIK, PRK, and SMILE.
• EVO ICL is presented as a superior alternative to LASIK, PRK, and SMILE due to its ability to preserve the tear film and cornea, offer UV protection, be reversible, and provide rapid recovery with improved contrast sensitivity and night vision.
• Unlike LASIK and PRK, EVO ICL does not induce dry eye syndrome, a common side effect of laser vision correction, as highlighted by studies cited in the presentation.
• The proprietary Collamer material used exclusively by STAAR is emphasized as a key differentiator, with other acrylic phakic IOLs having had 'limited success,' reinforcing STAAR's technological advantage and market leadership in the phakic IOL segment.

Stakeholder Impact

• Shareholders: Potential for short-term volatility due to the significant China sales decline and restructuring costs, but long-term growth potential if turnaround strategies are successfully executed and the myopia market expands as projected.
• Customers (Surgeons/Patients): Continued access to EVO ICL technology, with potential for improved supply chain efficiency and product availability following the Swiss manufacturing validation.
• Employees: Impact from restructuring and cost reduction initiatives, which may include severance and reduction in force.
• Distributors: Adjustment period as China distributors manage existing inventory, with an expected resumption of purchases in the near future.

Next Steps

• Validation of the Swiss manufacturing facility by Summer 2025.
• Planned resumption of purchases by China distributors commencing Q3 2025.
• Achieve a $225 million SG&A run rate by the end of FY25 through cost reduction actions.
• Return to historical earnings and cash flow generation.

Key Dates

Recommendation

Keywords

STAAR Surgical, STAA, EVO ICL, phakic IOLs, vision correction, myopia, refractive surgery, ophthalmology, Collamer, eye care, medical devices, SEC filing, investor presentation